3 Stocks Dragging The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 16,756 as of Friday, June 13, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,558 issues advancing vs. 1,369 declining with 183 unchanged.

The Drugs industry currently sits down 0.4% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the industry include United Therapeutics ( UTHR), down 4.0%, Novo Nordisk A/S ( NVO), down 1.6%, Biomarin Pharmaceutical ( BMRN), down 1.6%, Grifols ( GRFS), down 1.1% and Vertex Pharmaceuticals ( VRTX), down 0.9%. Top gainers within the industry include Mylan ( MYL), up 1.0%, Actavis ( ACT), up 0.8% and Forest Laboratories ( FRX), up 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Alexion Pharmaceuticals ( ALXN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Alexion Pharmaceuticals is down $2.29 (-1.4%) to $163.68 on light volume. Thus far, 515,916 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $162.63-$166.68 after having opened the day at $166.10 as compared to the previous trading day's close of $165.97.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $33.1 billion and is part of the health care sector. Shares are up 24.9% year-to-date as of the close of trading on Thursday. Currently there are 13 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, increase in net income and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $3.63 (-1.2%) to $306.84 on light volume. Thus far, 198,269 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 924,300 shares. The stock has ranged in price between $305.66-$311.69 after having opened the day at $310.68 as compared to the previous trading day's close of $310.47.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $30.7 billion and is part of the health care sector. Shares are up 12.8% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and weak operating cash flow. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Amgen ( AMGN) is down $0.70 (-0.6%) to $115.50 on light volume. Thus far, 512,282 shares of Amgen exchanged hands as compared to its average daily volume of 3.8 million shares. The stock has ranged in price between $115.50-$116.70 after having opened the day at $116.67 as compared to the previous trading day's close of $116.20.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $88.1 billion and is part of the health care sector. Shares are up 1.9% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Amgen a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Video: Jim Cramer Reveals Why Stocks Are Moving Lower Thursday

Video: Jim Cramer Reveals Why Stocks Are Moving Lower Thursday

Dow Falls, S&P 500 Lower as Amazon Rises, Apple and P&G Slump

Dow Falls, S&P 500 Lower as Amazon Rises, Apple and P&G Slump

Soaring Nickel Prices Could Be Bad News for Electric Carmakers Like Tesla

Soaring Nickel Prices Could Be Bad News for Electric Carmakers Like Tesla

Video: The Road to S&P 500 2,800 Is 'Slow and Choppy'

Video: The Road to S&P 500 2,800 Is 'Slow and Choppy'

Let the Najarian Brothers Help You Generate Income With Options

Let the Najarian Brothers Help You Generate Income With Options